Patents by Inventor Abdelazize Laoui

Abdelazize Laoui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CHEMICAL DERIVATIVES AND THEIR APPLICATION AS ANTITELOMERASE AGENTS
    Publication number: 20090226411
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: December 16, 2008
    Publication date: September 10, 2009
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Patrick MAILLIET, Abdelazize LAOUI, Jean-Francois RIOU, Gilles DOERFLINGER, Jean-Louis MERGNY, Francois HAMY, Thomas CAULFIELD
  • Chemical derivatives and their application as antitelomerase agents
    Patent number: 7482352
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: January 27, 2009
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Abdelazize Laoui, Jean-Francois Riou, Gilles Doerflinger, Jean-Louis Mergny, Francois Hamy, Thomas Caulfield
  • Chemical derivatives and their application as antitelomerase agents
    Patent number: 7179816
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: February 20, 2007
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Jean-Francois Riou, Marcel Alasia, Thomas Caulfield, Gilles Doerflinger, Jean-Louis Mergny, Abdelazize Laoui, Odile Petitgenet, Emmanuelle Renou
  • Triazine derivatives and their application as antitelomerase agents
    Patent number: 6887873
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: May 3, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Abdelazize Laoui, Jean-François Riou, Gilles Doerflinger, Jean-Louis Mergny, François Hamy, Thomas Caulfield
  • Chemical derivatives and their application as antitelomerase agents
    Publication number: 20050070575
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: September 30, 2004
    Publication date: March 31, 2005
    Applicant: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Jean-Francois Riou, Marcel Alasia, Thomas Caulfield, Gilles Doerflinger, Jean-Louis Mergny, Abdelazize Laoui, Odile Petitgenet, Emmanuelle Renou
  • Chemical derivatives and their application as antitelomerase agents
    Patent number: 6858608
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: January 9, 2002
    Date of Patent: February 22, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Jean-François Riou, Marcel Alasia, Thomas Caulfield, Gilles Doerflinger, Jean-Louis Mergny, Abdelazize Laoui, Odile Petitgenet, Emmanuelle Renou
  • Chemical derivatives and their application as antitelomerase agent
    Publication number: 20040053966
    Abstract: The present invention relates to cancer therapy and to novel anticancer agent having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: September 10, 2003
    Publication date: March 18, 2004
    Applicant: Aventis Pharms S.A.
    Inventors: Patrick Mailliet, Jean-Francois Riou, Jean-Louis Mergny, Abdelazize Laoui, Francois Lavelle, Odile Petitgenet
  • Chemical derivatives and their application as antitelomerase agent
    Patent number: 6645964
    Abstract: The present invention relates to cancer therapy and to novel anticancer agent having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: November 11, 2003
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Mailliet, Jean-François Riou, Jean-Louis Mergny, Abdelazize Laoui, François Lavelle, Odile Petitgenet
  • Chemical derivatives and their application as antitelomerease agent
    Publication number: 20030087931
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: March 25, 2002
    Publication date: May 8, 2003
    Inventors: Patrick Mailliet, Abdelazize Laoui, Jean-Francois Riou, Gilles Doerflinger, Jean-Louis Mergny, Francois Hamy, Thomas Caulfield
  • Chemical derivatives and their application as antitelomerase agents
    Publication number: 20030078263
    Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which inhibits telomerase. It also relates to novel chemical compounds as well as their therapeutic application in humans.
    Type: Application
    Filed: January 9, 2002
    Publication date: April 24, 2003
    Inventors: Patrick Mailliet, Jean-Francois Riou, Marcel Alasia, Thomas Caulfield, Gilles Doerflinger, Jean-Louis Mergny, Abdelazize Laoui, Odile Petitgenet, Emmanuelle Renou
  • Chemical derivatives and their application as antitelomerase agents
    Publication number: 20030013711
    Abstract: The present invention relates to cancer therapies using novel anticancer agents with a specific mechanism of action. The invention also relates to novel chemical compounds and their therapeutic application in man.
    Type: Application
    Filed: February 22, 2002
    Publication date: January 16, 2003
    Inventors: Patrick Mailliet, Jean-Francois Riou, Abdelazize Laoui, Jean-Louis Mergny, Sylvie Gontier
  • Chemical derivatives and use thereof as antitelomerase agents
    Publication number: 20020103169
    Abstract: Novel anticancer agents of the phenanthridine class having a specific mechanism of action and cancer therapy methods are described, including the novel chemical compounds and their therapeutic use thereof in humans.
    Type: Application
    Filed: August 8, 2001
    Publication date: August 1, 2002
    Inventors: Patrick Mailliet, Jean-Francois Riou, Jean-Louis Mergny, Abdelazize Laoui